Hill Holliday Health launches inside its Boston-based parent agency

Hill Holliday Health launches with executive creative director David Leonardi and managing director Scott Rabschnuk at the helm. (Business Wire)

Boston ad agency Hill Holliday has been doing pharma and healthcare work for years. But not many people seemed to know about it. So last week, the agency created a health-specific branded agency within itself with the launch of Hill Holliday Health.

The agency made a conscious decision years ago to not brand as a healthcare agency in order to stand out with its consumer approach in the busy healthcare marketing arena, managing director Scott Rabschnuk explained. But more recently, Hill Holliday discovered that, especially when it came to recruiting health marketing talent, people would say they “didn’t even know you guys did healthcare."

RELATED: FCB Health launches stand-alone agency for pharma and healthcare branding

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“We realized we weren’t on the radar, so we were having a hard time attracting talent and we probably weren’t getting our fair share of at-bats with clients,” he said. “We can still be that consumer-oriented healthcare organization and our work speaks for itself, but we need to brand ourselves and give ourselves an identity so that both prospective clients as well as great industry talent, knows we’re on the map.”

The 120-person workforce of Hill Holliday Health will continue its work for pharma clients such as Novartis and Johnson & Johnson’s Janssen for brands Xarelto and Invokana, as well as pitch for new business and look to hire more healthcare talent.

Suggested Articles

Array's combo for BRAF-positive colon cancer could be a blockbuster, analysts say—but only if it can prove safety and durability.

With Congress railing against insulin list prices, Eli Lilly promised a cheaper generic Humalog in a show of good faith. Consider that promise kept.

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.